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a heart failure (HF) center.Background In advanced HF, the criteria for heart transplantation, left ventricular assist device, and palliative care are well known
among HF specialists, but criteria for referral to an advanced HF center have not been developed for generalists.Methods We assessed observed and expected all-cause mortality in 10,062 patients with New York Heart Association (NYHA)
functional class III to IV HF and ejection fraction <40% registered in the Swedish Heart Failure Registry between
2000 and 2013. Next, 5 pre-speciﬁed universally available risk factors were assessed as potential triggers for
referral, using multivariable Cox regression: systolic blood pressure 90 mm Hg; creatinine 160 mmol/l;
hemoglobin 120 g/l; no renin-angiotensin system antagonist; and no beta-blocker.Results In NYHA functional class III to IV and age groups 65 years, 66 to 80 years, and >80 years, there were 2,247,
4,632, and 3,183 patients, with 1-year observed versus expected survivals of 90% versus 99%, 79% versus 97%,
and 61% versus 89%, respectively. In the age 80 years group, the presence of 1, 2, or 3 to 5 of these risk factors
conferred an independent hazard ratio for all-cause mortality of 1.40, 2.30, and 4.07, and a 1-year survival of 79%,
60%, and 39%, respectively (p < 0.001).Conclusions In patients 80 years of age with NYHA functional class III to IV HF and ejection fraction <40%, mortality is
predominantly related to HF or its comorbidities. Potential heart transplantation/left ventricular assist device
candidacy is suggested by 1 risk factor and potential palliative care by multiple universally available risk factors.
These patients may beneﬁt from referral to an advanced HF center. (J Am Coll Cardiol 2014;63:661–71)
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evised manuscript received September 16, 2013,Heart failure (HF) affects 2% of the Western population
(1–4) and is associated with poor quality of life and high
mortality. Pharmacologic therapy, cardiac resynchronization
therapy (CRT), and implantable cardioverter-deﬁbrillators
(ICDs) have improved prognosis in HF with reduced ejec-
tion fraction (EF) but have also increased the number of
patients living with advanced HF. Improved survival after
acute coronary syndromes and aging of the population are
further contributing to an increased prevalence of HF.
Thus, there is an unmet and growing need for advanced
HF therapy (1–3).
Heart transplantation (HTx) and left ventricular assist
devices (LVADs) improve quality of life and survival in
advanced HF (4–6). LVADs are used mainly as bridge to
transplantation (BTT), but with donor organ shortage
and improving outcomes with continuous ﬂow devices, they
are increasingly being used as permanent therapy, or desti-
nation therapy (DT) (7). Palliative care improves quality of
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662life and is indicated in refrac-
tory HF, especially if HTx and
LVAD are ruled out (2,8).
However, patients with ad-
vanced HF are believed to be un-
derserved by these treatments
(1,3,5,6,8,9). Reasonsmay include
HF care performed by generalists
with lack of awareness of prog-
nosis and indications for advanced
treatment, and inadequate or de-
layed referral to advanced HF
centers, which are best suited to
perform triage to different inter-
ventions. Indeed, although there
arewell-established criteria forHF
specialists performing in particular
HTx and LVAD selection, there
are no tools or criteria for gener-
alists to determine who to refer
for evaluation.Therefore, the aims were: ﬁrst, to assess the contempo-
rary observed and expected survival in an unselected pop-
ulation with New York Heart Association (NYHA)
functional class III to IV HF and reduced EF; and second,
to test the hypothesis that simple universally available vari-
ables can independently predict prognosis and can be used
as triggers for referral to advanced HF centers. Because
NYHA functional class II versus III is a subjective dis-
tinction and many clinicians base referrals on symptoms
alone, we also assessed the triggers separately in NYHA
functional class II.Methods
Study protocol. The Swedish Heart Failure Registry
has been previously described (10). The inclusion criterium
is clinician-judged HF. Eighty variables are recorded at
discharge from hospital or outpatient visit and entered into
a Web-based database managed by the Uppsala Clinical
Research Center (Uppsala, Sweden). The database is run
against the Swedish death registry monthly. (The protocol,
registration form, and annual report are available at www.
rikssvikt.se.) Establishment of the registry and analysis of
data was approved by a multisite ethics committee and
conforms to the Declaration of Helsinki. Individual patient
consent is not required, but patients are informed of entry
into national registries and are allowed to opt out.
Between May 11, 2000, and June 5, 2013, there
were 85,291 registrations from 68 of approximately 75
hospitals and 102 of approximately 1,000 primary care
outpatient clinics in Sweden. Of these, there were 10,062
ﬁrst registrations with NYHA functional class III to IV
and EF <40% and 9,463 ﬁrst registrations with NYHA
functional class II and EF <40%. The main analysis was
NYHA functional class III to IV and included baselinecharacteristics, observed and expected all-cause mortality,
and risk factors for all-cause mortality. The separate
analysis was NYHA functional class II and included
baseline characteristics and risk factors for all-cause
mortality (Fig. 1).
Statistical analysis. Statistical analysis was performed in R
version 2.15.3 (R Foundation for Statistical Computing,
Vienna, Austria). The level of signiﬁcance was set to 5%,
and all reported p values and conﬁdence intervals (CIs) are
2-sided.
Baseline characteristics. Forty-six clinically-relevant base-
line variables were included for analysis (Table 1) and were
compared among 3 age groups: 65 years, 66 to 80 years,
and >80 years. The age cut-offs were based on general
European practice: HTx considered mainly for age 65
years, DT-LVAD for patients in their 70s, and for carefully
selected patients, up to age 80 years; and palliation for age
>80 years or for younger patients with contraindications to
HTx or LVAD.
Observed and expected all-cause mortality. Observed
mortality for the overall study population and the 3 age
groups was charted with the Kaplan-Meier method together
with the expected mortality (Fig. 2). The expected mortality
is for the study population if it had the same mortality
probability as the general Swedish population matched to
the sex, age, and year of observation of the study population
(11). The mortality probabilities for the Swedish population
were obtained from the Human Mortality database (http://
www.mortality.org). The difference between observed and
expected yields the “excess” mortality, which can be inter-
preted as the mortality related to HF itself and/or to asso-
ciated comorbidities.
Risk factors for all-cause mortality. Because patients with
advanced HF and age >80 years are generally not candidates
for HTx or LVAD and are generally agreed to be suitable for
palliation, they were excluded from the following risk factor
analysis (Fig. 1).
Five simple and universally available variables, and cut-
offs for continuous variables, were prospectively selected as
potential independent risk factors for all-cause mortality
based on previous studies (12–15) and as potential triggers
for referral to an HF center (Table 2): systolic blood pres-
sure 90 mm Hg (a criterion for cardiogenic shock);
creatinine 160 mmol/l (which represents considerable
end-organ impairment but generally not yet a contraindica-
tion to HTx or LVAD [15]); hemoglobin 120 g/l
(a marker of the cardiorenal syndrome and progressive HF
[15]); and absent renin-angiotensin system antagonist or
beta-blocker treatment (12,15). We cannot show that absent
drug therapy is due to intolerance, and certainly every effort
should be made to utilize these medications. However,
whether the lack of drug therapy is because of true intoler-
ance or is a reﬂection of the generalist’s perception of patient
frailty or unease about follow-up and monitoring, both of
these reasons warrant referral to an advanced HF center for
optimization.
Figure 1 Flow Chart, All Patients
Patient inclusion and exclusion. EF ¼ ejection fraction; NYHA ¼ New York Heart Association.
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663Twelve additional secondary variables were selected for
assessment of prognostic utility (Fig. 3). Continuous variables
contain more information when analyzed continuously, but
for ease of interpretation and, importantly, for ease of use
as referral criteria (5 variables) and prognostic markers (12
secondary variables), they were categorized at cut-offs that
were previously shown or proposed to be prognostically useful
(12–15).
A multivariable Cox regression, using the Efron method
for tie handling, was performed with all 46 baseline vari-
ables, and the hazard ratios (HRs) for mortality associated
with each of the 5 risk factors (Table 2, parts A and B) and
secondary 12 pre-speciﬁed risk factors were displayed in
a Forest plot (Fig. 3). To assess the HR associated with
cumulative number of risk factors, another Cox regression
was performed in which a new variable “number of risk
factors” was included, and the 5 risk factors themselves were
excluded, yielding 42 variables (Table 2, parts C and D).
The proportional hazards assumption was investigated
for the scaled Schoenfeld residuals from the model con-
taining 46 variables. In the main NYHA functional class III
to IV analysis, NYHA functional class exhibited non-
proportional hazards; therefore, a consistency Cox analysis
was performed in which the time axis for NYHA functionalclass was partitioned into 6 months and >6 months. The
dfbetas (a measure of how much the HR changes due to the
deletion of a single observation) from the models were
inspected for outliers (16), but no problems were detected.
The pre-speciﬁed continuous risk factors were categorized,
but for remaining continuous variables, the assumption of
linearity was investigated by smoothed Martingale residuals
plots and found to be acceptably linear in relation to
mortality.
To avoid bias and confounding due to baseline variables
missing not at random, multiple imputation (n ¼ 10) (are-
gImpute [Hmisc] in R) was performed using predictive
mean matching. The imputation model was for all patients,
NYHA functional class II to IV, and included the 46
numbered variables in Table 1, and the outcome, all-cause
mortality, was included as the Nelson-Aalen estimator but
was not imputed itself because it contained no missing
values. Mortality was assessed with the Kaplan-Meier
method for each of the 5 risk factors separately and
according to the cumulative number of pre-speciﬁed risk
factors, 0 to 5 (Table 2, Fig. 4).
To assess concordance between model predictions and
observed outcomes, c-indexes (17) were calculated: 1) for
the multivariable Cox regression model including all 46
Table 1 Baseline Characteristics by Age Group, NYHA Functional Class III to IV
Variable
Age 65 yrs
(n ¼ 2,247)
Age 66–80 yrs
(n ¼ 4,632)
Age >80 yrs
(n ¼ 3,183)
Follow-up time, days 1,134 (1–4,497) 762 (0–4,515) 430 (0–3,925)
Number dead 618 (28%) 2,359 (51%) 2,251 (71%)
Demographics
Female 520 (24%) 1,271 (27%) 1,184 (37%)
Civil status
Single 854 (40%) 1,572 (35%) 1,590 (52%)
Married/cohabitating 1,294 (60%) 2,875 (65%) 1,482 (48%)
Living arrangements
Institution 66 (4%) 111 (4%) 227 (11%)
Independent 1,437 (96%) 3,034 (96%) 1,930 (89%)
Location at enrollment
Inpatient 1,004 (45%) 2,288 (49%) 2,111 (66%)
Outpatient physician 129 (6%) 310 (7%) 170 (5%)
Outpatient HF nurse 1,111 (50%) 2,031 (44%) 901 (28%)
Specialty
Cardiology 1,406 (63%) 2,517 (56%) 1,523 (49%)
Internal medicine/geriatrics 818 (37%) 2,014 (44%) 1,582 (51%)
Year of registration
2000–2005 300 (13%) 682 (15%) 402 (13%)
2006–2013 1,947 (87%) 3,950 (85%) 2,781 (87%)
Duration of HF 6 months 1,060 (47%) 2,925 (63%) 2,111 (67%)
Clinical
NYHA functional class
III 2,068 (92%) 4,139 (89%) 2,689 (84%)
IV 179 (8%) 493 (11%) 494 (16%)
Ejection fraction
30%–39% 699 (31%) 1,908 (41%) 1,510 (47%)
<30% 1,548 (69%) 2,724 (59%) 1,673 (53%)
BMI 22 kg/m2 160 (14%) 407 (19%) 450 (32%)
Systolic BP 90 mm Hg 224 (10%) 294 (6%) 170 (5%)
Pulse pressure, mm Hg 43  15 50  16 53  17
Heart rate 70 beats/min 1,425 (68%) 2,725 (63%) 1,927 (65%)
Chest radiograph
Cardiomegaly 878 (58%) 1,785 (55%) 1,261 (55%)
Deﬁnite congestion 688 (45%) 1,578 (48%) 1,293 (56%)
Continued on the next page
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factors; and 3) for a model containing only 1 variable deﬁned
as “number of risk factors” (n ¼ 0 to 5).
Results
Baseline characteristics. In NYHA functional class III to
IV, age groups 65 years, 66 to 80 years, and >80 years,
there were 2,247, 4,632, and 3,183 patients, respectively.
Younger patients were more commonly male with lower
EF but otherwise generally healthier and with more
evidence-based treatment (Table 1). The NYHA functional
class II patients were younger and generally healthier than
the NYHA functional class III to IV patients, but the
differences between age groups exhibited similar patterns
(Online Table 1).
Observed and expected all-cause mortality. For NYHA
functional class III to IV, overall observed 1- and 5-yearsurvival was 76% and 39%, respectively, and expected
survival was 95% and 76%, respectively (Fig. 2A). The cor-
responding ﬁgures by age group were as follows: age 65
years, 90% and 68% observed versus 99% and 96% expected;
age 66 to 80 years, 79% and 40% observed versus 97% and
83% expected; and age >80 years, 61% and 17% observed
versus 89% and 52% expected (Figs. 2B and 2D). The
absolute difference between observed and expected mortality
(“excess mortality,” distance between curves) was similar for
all age groups, but the relative difference (distance between
curves in proportion to actual mortality) was dramatically
higher in the 65 years and 66 to 80 years age groups
compared with the >80 years group.
Risk factors for all-cause mortality. Table 2, part A, and
Figure 3 depict the 5 risk factors for all-cause mortality
for NYHA functional class III to IV. Hemoglobin 120 g/l
was the most common risk factor. All 5 risk factors and most
Table 1 Continued
Variable
Age 65 yrs
(n ¼ 2,247)
Age 66–80 yrs
(n ¼ 4,632)
Age >80 yrs
(n ¼ 3,183)
Laboratory
Creatinine 160 mmol/l 149 (7%) 676 (15%) 715 (22%)
Potassium, mEq/l 4.2  0.5 4.2  0.5 4.2  0.5
Hemoglobin 120 g/l 364 (16%) 1,204 (26%) 1,084 (34%)
NT-proBNP 2,000 pg/ml 524 (60%) 1,116 (73%) 796 (86%)
Medical history
Hypertension 807 (37%) 2,163 (48%) 1,504 (49%)
Diabetes mellitus
No 1,607 (72%) 3,047 (66%) 2,439 (77%)
Type 2, diet treated 104 (5%) 284 (6%) 175 (6%)
Type 2, orally treated 163 (7%) 397 (9%) 200 (6%)
Type 2, insulin and orally treated 107 (5%) 197 (4%) 60 (2%)
Type 1 or 2, insulin treated 253 (11%) 678 (15%) 283 (9%)
Smoking
Never 554 (28%) 1,353 (36%) 1,183 (54%)
Former 888 (45%) 1,924 (51%) 926 (42%)
Yes 528 (27%) 482 (13%) 101 (5%)
Ischemic heart disease 813 (38%) 2,736 (62%) 1,980 (65%)
Dilated cardiomyopathy 847 (39%) 825 (18%) 279 (9%)
Hypertrophic cardiomyopathy 39 (3%) 74 (2%) 44 (2%)
Valve disease 373 (17%) 1,055 (23%) 949 (31%)
Atrial ﬁbrillation/ﬂutter 738 (33%) 2,352 (51%) 1,766 (56%)
Lung disease 388 (18%) 1,058 (23%) 550 (18%)
Medications
No RAS antagonist 101 (5%) 448 (10%) 684 (22%)
No b-blocker 133 (6%) 451 (10%) 485 (15%)
No MRA 1,180 (53%) 2,747 (60%) 2,187 (69%)
Digoxin 427 (19%) 901 (20%) 547 (17%)
Diuretic 1,875 (84%) 4,085 (89%) 2,900 (92%)
Nitrates 192 (9%) 861 (19%) 869 (27%)
Amiodarone 78 (5%) 136 (4%) 47 (2%)
Aspirin 977 (44%) 2,287 (50%) 1,833 (58%)
Oral anticoagulant 988 (44%) 2,147 (47%) 1,001 (32%)
Statin 1,032 (46%) 2,570 (56%) 1,157 (37%)
History of interventions
PCI and/or CABG 564 (26%) 1,669 (37%) 806 (26%)
Valve intervention 118 (5%) 332 (7%) 151 (5%)
Pacemaker 84 (4%) 433 (9%) 480 (15%)
No CRT 2,065 (93%) 4,272 (93%) 3,076 (98%)
No ICD 1,996 (90%) 4,291 (93%) 3,110 (99%)
Planned follow-up
Specialty
Cardiology/internal medicine 1,890 (90%) 3,185 (75%) 1,271 (45%)
Primary care 153 (7%) 892 (21%) 1,387 (50%)
Other 59 (3%) 157 (4%) 143 (5%)
Nurse-based HF clinic 1,329 (63%) 2,192 (52%) 938 (33%)
Values are n (%) or mean  SD with the exception of follow-up, which is median (minimum–maximum).
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; CRT ¼ cardiac resynchronization therapy; HF ¼ heart failure; ICD ¼ implantable
cardioverter-deﬁbrillator; MRA ¼ mineralocorticoid receptor antagonist; NT-proBNP ¼ N-terminal pro-brain natriuretic peptide; NYHA ¼ New York
Heart Association; PCI ¼ percutaneous coronary intervention; RAS ¼ renin-angiotensin system.
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665of the 12 pre-speciﬁed risk factors were independent
predictors of mortality. Creatinine 160 mmol/l was asso-
ciated with the highest HR. Table 2, part B, and Figure 4
depict mortality by number of risk factors for NYHA
functional class III to IV. Number of risk factor distribution
was as follows: 0, 59%; 1, 28%; 2, 10%; 3 to 5, 3%. In otherwords, 41% of patients had at least 1 risk factor. The
presence of 0 to 5 risk factors was associated with progres-
sively worse survival; 0 risk factors (90% 1-year survival) was
similar to a post-HTx prognosis (18) and 1 risk factor (79%
1-year survival) was similar to a post-LVAD prognosis (19).
Two risk factors and 3 to 5 risk factors were associated
Years
Su
rv
iva
l r
a
te
s 
(%
)
0 1 2 3 4 5 6
0
20
40
60
80
100
Study population
Swedish population with gender, age and year as study population
No. at risk 10062 6834 4950 3567 2381 1524 880
Years
Su
rv
iva
l r
a
te
s 
(%
)
0 1 2 3 4 5 6
0
20
40
60
80
100
Study population
Swedish population with gender, age and year as study population
No. at risk 2247 1808 1468 1159 850 592 364
Years
Su
rv
iva
l r
a
te
s 
(%
)
0 1 2 3 4 5 6
0
20
40
60
80
100
Study population
Swedish population with gender, age and year as study population
No. at risk 4632 3303 2374 1729 1151 723 422
Years
Su
rv
iva
l r
a
te
s 
(%
)
0 1 2 3 4 5 6
0
20
40
60
80
100
Study population
Swedish population with gender, age and year as study population
No. at risk 3183 1723 1108 679 380 209 94
A B
C D
Figure 2 Observed and Expected All-Cause Mortality, NYHA Functional Class III to IV
(A) Overall; (B) age 65 years; (C) age 66 to 80 years; (D) age >80 years. The expected mortality is for the study population if it had the same mortality probability
as the general Swedish population matched to the sex, age, and year of observation of the study population. NYHA ¼ New York Heart Association.
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666with 60% and 39% 1-year survival, respectively. The HR
increased progressively by number of risk factors: 1.40, 2.30,
and 4.07 for 1, 2, and 3 to 5 risk factors, respectively, versus
0 risk factors (Table 2, part B). The HR for NYHA func-
tional class IV versus III was 1.39 (95% CI: 1.25 to 1.55,
p < 0.001). With partitioned functional class time axis
for NYHA functional class, the HR for NYHA functional
class IV versus III was 3.02 (95% CI: 2.58 to 3.54,
p < 0.001) for the ﬁrst 6 months of follow-up and 0.83
(95% CI: 0.71 to 0.97, p ¼ 0.020) thereafter. Partitioned
NYHA functional class time axis in the Cox regression did
not alter the results for the other variables.
Table 2, parts C and D, and Figure 4B show data for the
separate NYHA functional class II analysis. The 5 riskfactors were less common in NYHA functional class II.
As expected, the absolute risk was lower; namely, overall
survival for any given risk factor and for any given number
of risk factors was higher in NYHA functional class II.
Systolic blood pressure 90 mm Hg and absent beta-
blocker were rare and were not signiﬁcant alone. The
“number of risk factors” was highly signiﬁcant, but the HR
associated with any given risk factor or with any given
number of risk factors was slightly lower in NYHA func-
tional class II than NYHA functional class III to IV.
In NYHA functional class III to IV, the c-indexes for the
model containing the 5 risk factors and for the model with
only 1 variable deﬁned as “number of risk factors” were 0.71
and 0.73, respectively. The c-index for the multivariable
Table 2
Five Pre-Speciﬁed Risk Factors and Survival by Each Risk Factor and by
Cumulative Number of Risk Factors, Patients Age 80 Years, NYHA Functional Class III to IV,
and NYHA Functional Class II
Risk Factor n Dead/n Total 1-Yr Survival HR 95% CI p Value
A. NYHA functional class III–IV risk factor*
Systolic BP 90 mm Hg 304/520 68% 1.64 1.43–1.88 <0.001
Systolic BP >90 mm Hg 2,673/6,359 84%
Creatinine 160 mmol/l 611/827 58% 1.91 1.72–2.12 <0.001
Creatinine <160 mmol/l 2,366/6,052 86%
Hemoglobin 120 g/l 929/1,568 69% 1.32 1.21–1.43 <0.001
Hemoglobin >120 g/l 2,048/5,311 86%
Not treated with RAS antagonist 401/559 58% 1.56 1.39–1.75 <0.001
Treated with RAS antagonist 2,576/6,320 85%
Not treated with b-blocker 352/587 71% 1.28 1.14–1.44 <0.001
Treated with b-blocker 2,625/6,292 84%
B. NYHA functional class III–IV, no. of
risk factorsy
0 1,262/3,905 90%
1 944/1,870 79% 1.40z 1.28–1.53 <0.001
2 488/672 60% 2.30z 2.05–2.57 <0.001
3–5 186/221 39% 4.07z 3.44–4.82 <0.001
C. NYHA functional class II, risk factor*
Systolic BP 90 mm Hg 69/268 91% 1.10 0.85–1.43 0.477
Systolic BP >90 mm Hg 1,630/7,304 94%
Creatinine 160 mmol/l 183/354 79% 1.74 1.46–2.07 <0.001
Creatinine <160 mmol/l 1,516/7,218 95%
Hemoglobin 120 g/l 385/1,043 87% 1.37 1.21–1.55 <0.001
Hemoglobin >120 g/l 1,314/6,529 95%
Not treated with RAS antagonist 126/293 84% 1.28 1.05–1.55 0.014
Treated with RAS antagonist 1,573/7,279 94%
Not treated with b-blocker 138/487 93% 1.16 0.97–1.39 0.113
Treated with b-blocker 1,561/7,085 94%
D. NYHA functional class II, no. of risk factorsy
0 1,005/5,457 96%z
1 474/1,566 91%z 1.36 1.21–1.53 <0.001
2 142/317 84%z 1.81 1.50–2.18 <0.001
3–5 37/57 66%z 2.64 1.84–3.77 <0.001
*From 46-variable Cox regression. Presented number dead and number total are mean of 10 imputed datasets. yFrom Cox regression where the 5 risk
factors themselves have been excluded and a new variable, “number of risk factors,” has been added, yielding 42 variables in the Cox regression analysis.
zHazard ratio (HR) compared with 0 risk factors.
BP ¼ blood pressure; CI ¼ conﬁdence interval; other abbreviations as in Table 1.
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667Cox regression model including all 46 baseline variables
was 0.75. In NYHA functional class II, the corresponding
c-indexes were 0.69, 0.69, and 0.75.
Discussion
In a large, unselected population age 80 years with
NYHA functional class III to IV HF and EF <40%: 1)
mortality was mainly directly or indirectly related to HF
and/or its comorbidities; and 2) the presence of any 1 or
more of 5 pre-speciﬁed universally available risk factors
conferred a 1-year survival of 79% or worse, and could thus
identify patients who may beneﬁt from referral to an
advanced HF center. Also for patients with NYHA func-
tional class II HF, the risk factor model was predictive of
relative risk, but calibration and suitability as a referral tool
was worse.Under-referral for advanced HF therapy. Before
advanced therapy consideration, basic HF therapy should
be optimized. The 5% to 22% untreated with renin-
angiotensin system antagonists or beta-blockers in our study
was better than in other observational HF studies (20).
However, fewer than one-half of patients received mineral-
ocorticoid receptor antagonists, and only 1% to 11% received
CRT and/or ICD, which certainly should be improved.
However, advanced HF therapy likely remains underutilized
(1,3,5,6,8,9). One-year survival after HTx approaches 90%
(18), and 1-year survival with LVAD now approaches 80%
(7,19). In the United States, an estimated 100,000 people
would beneﬁt from HTx (5,6), and 25,000 to 250,000 may
beneﬁt from LVAD, primarily as DT (1,3). Yet, there
are only 2,200 HTx (18) and 1,800 LVADs performed
annually (7). Utilization of palliative care varies considerably
and is substantially less for HF than for cancer (21).
Figure 3 Hazard Ratios and 95% CIs for All-Cause Mortality
Hazard ratios and 95% conﬁdence intervals (CIs) for all-cause mortality for the 5 main and 12 additional pre-speciﬁed risk factors, New York Heart Association (NYHA) functional
class III to IV, from the 46-variable Cox regression analysis, patient age 80 years. ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin-receptor blocker; BMI ¼
body mass index; CRT ¼ cardiac resynchronization therapy; EF ¼ ejection fraction; ICD ¼ implantable cardioverter-deﬁbrillator; MRA ¼ mineralocorticoid receptor antagonist;
NT-proBNP ¼ N-terminal pro-brain natriuretic peptide.
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668The main reason for underutilization of HTx is donor
organ shortage (5). Although organs are increasingly going to
high urgency or LVAD patients, even the listing of ambu-
latory patients has decreased dramatically (6). Earlier referral
may not increase the total number of HTx, but would identify
potential candidates early and allow careful monitoring and
optimal timing for HTx and/or BTT-LVAD if needed. The
reasons for under-referral for LVAD are unknown. BTT-
LVAD is generally accepted but referrals are often too late,
with prohibitive right ventricular or end-organ failure (4,7).
DT-LVAD has not been widely adopted, possibly because of
poor awareness and slow acceptance among referring physi-
cians, remaining debates amongHF specialists (1,22,23), and
limited patient acceptance (24).
However, the major reason for underutilization is likely
unawareness and difﬁculty for generalists in assessing the
need. In Sweden, more than one-half of patients with HF
are cared for exclusively by primary care physicians (25),
which may in part explain our observed low penetrance of
CRT and ICD. In our study, nearly one-half of patients
were seen by internal medicine/geriatrics, and follow-up was
in primary care in 7% to 50%, despite being in NYHAfunctional class III to IV and EF <40%. In Sweden,
a majority of hospitals have an HF nurse clinic, and referral
occurred in 33% to 63% of patients, but few of these clinics
have expertise in HTx or LVAD selection, and most lack
formal palliative care programs.
Prognostic tools such as the peak VO2, the Heart
Failure Survival Score (HFSS), the Seattle Heart Failure
Model (SHFM), and the recent MAGGIC (Meta-Analysis
Global Group in Chronic Heart Failure) risk score
(4,6,13,26,27) are well known among HF specialists but
may be too complex for busy generalists. Even with these
tools, prognosis remains notoriously difﬁcult to predict (28).
NYHA functional class discriminates well (HR: 1.39 for
NYHA functional class IV vs. III in our study) but is
subjective, is variable (nonproportional hazards), and does
not calibrate well (cannot be used alone as a referral crite-
rion). Therefore, we assessed our model also in NYHA
functional class II. With better overall prognosis, the cali-
bration as a tool for referral for advanced therapy was worse.
Namely, in NYHA functional class II, 1-year survival with 1
risk factor was 91% (vs. 79% in NYHA functional class III
to IV) and with 2 risk factors, 84% (vs. 60% in NYHA
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Figure 4 Observed All-Cause Mortality by Number of Pre-Speciﬁed Risk Factors
Observed all-cause mortality by number of pre-speciﬁed risk factors for (A) New York Heart Association (NYHA) functional class III to IV and (B) NYHA functional class II, for
patients age 80 years. The pre-speciﬁed risk factors were systolic blood pressure 90 mm Hg, creatinine 160 mmol/l, hemoglobin 120 g/l, no treatment with renin-
angiotensin system antagonist, and no treatment with beta-blocker (Table 2). For comparison, the approximate 1-year survival for heart transplantation (90%) (18) and left
ventricular assist device (80%) (19) are marked with dotted lines. The 5 risk factors themselves and the “number of risk factors” variable were not imputed; 211 NYHA
functional class III to IV patients and 475 NYHA functional class II patients with any of the 5 risk factors missing were excluded.
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669functional class III to IV), and the simple 1 risk factor
criterion was no longer applicable. The risk factor model was
still predictive of relative risk, but discrimination, as
measured by area under the curve, was slightly lower in
NYHA functional class II compared with NYHA functional
class III to IV. The risk factors are related to the severity
of HF and are thus less common in NYHA functional class
II, but once present, they may signify progressive decline
and should certainly be considered when assessing risk, and
they may justify referral even if the subjective NYHA
functional class assessment is only II.
With elderly patients, clinicians may underestimate the
symptomatic and prognostic role of HF relative to age itself.
However, in our patients age 80 years, mortality was
primarily HF and/or comorbidity related (and thus poten-
tially treatable with HF therapy) rather than from age. It is
likely that comorbidities (e.g., a risk factor for HF such as
hypertension) cause death independently of HF (e.g., fatal
stroke). Thus, although 41% of patients age 80 years had
at least 1 of 5 risk factors and thus higher mortality than
after HTx or LVAD, we certainly do not suggest that all
would beneﬁt from or be candidates for such treatment.
However, in well-selected elderly, DT-LVAD is associated
with favorable outcomes (19), and regardless of the relative
roles of HF and age, the elderly should not be excluded from
referral for expert evaluation, optimal symptom relief, and
palliation if indicated.
Five simple and universally available triggers to improve
referral. In the NYHA functional class III to IV analysis,
the 90% and 79% 1-year survival in the age 65 years groupand the 66 to 80 years group, respectively, was better than
the overall 70% to 80% in other unselective observational
studies (29). However, with only 1 of the 5 risk factors,
1-year survival in the age 80 years group dropped to 79%,
worse than after HTx and LVAD (18,19), and with addi-
tional risk factors, prognosis worsened considerably, sug-
gesting these risk factors may be useful triggers for referral to
advanced HF centers. Peak VO2 <12 to 14 ml/kg/min and
medium-high risk HFSS criteria for HTx correspond
to <80% to 90% 1-year survival (13,26). Analogously, the
correspondence of 1 risk factor with 79% 1-year survival,
worse than after HTx (18) and similar to LVAD (19),
suggests proper calibration and utility for referral to an
advanced HF center. However, 1 risk factor certainly does
not automatically confer an indication for HTx or LVAD.
Indeed, the appropriateness of and criteria for DT-LVAD
continue to be debated (1,22,23). Instead, it serves as
a proposed trigger for referral to an advanced HF center,
where detailed indications and contraindications and
potential other interventions can be assessed. For NYHA
functional class II, >1 risk factor was needed for a prognosis
worse than post-HTx or LVAD, but the risk factors were
still predictive of increased relative risk. Thus, referral may
still be reasonable if numerous risk factors are present or the
distinction between NYHA functional class II versus III is
difﬁcult.
Renal function is better assessed by glomerular ﬁltration
rate than by creatinine. Continuous variables (blood pres-
sure, creatinine, hemoglobin) provide more statistical reso-
lution when assessed continuously rather than categorically.
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670However, importantly, our aim was not to validate predictors
with optimal resolution but to provide simple, universally
available, and memorable criteria that do not require calcu-
lation (e.g., glomerular ﬁltration rate) or access to risk
models (e.g., HFSS, SHFM, or MAGGIC) and that can
help generalist clinicians quickly identify patients with poor
prognosis who may beneﬁt from referral to an advanced HF
center. In the NYHA functional class III to IV analysis, the
discriminatory performance of the simple 5 variables alone
(c-index 0.71) and of the simple “number of risk factors”
(n ¼ 0 to 5) variable (c-index 0.73) was close to that of the
complete model based on 46 variables (c-index 0.75), was
better than that for the peak VO2, and was similar to the
HFSS and SHFM (13) in HTx-referred patients. The 12
additional risk factors were also generally predictive of
mortality, suggesting that, for example, longer duration of
HF, ischemic etiology, progressively increasing N-terminal
pro-brain natriuretic peptide, and of course NYHA func-
tional class IV should also raise concern. However, these
factors may be difﬁcult to assess or unavailable in generalist
settings. In contrast, the 5 main risk factors are completely
objective and universally available and were also among the
strongest predictors (Fig. 3).
Thus, we propose that referring generalists should not
focus on cumbersome detailed criteria for HTx, LVAD, or
palliative care, but instead should rely on simple, universally
available triggers for referral to advanced HF centers. All
5 risk factor variables have previously been shown to be
independent predictors of mortality, but generally with
less covariate adjustment and not as speciﬁc referral cri-
teria (12–15). Although the c-index was high, we do not
suggest that our simple model provides superior prognosti-
cation compared with sophisticated selection tools (12,13).
However, we do propose that our universally available
criteria are simpler and more likely to be used in generalist
care and emphasize that they should be used for referral, not
for selection. Although our proposed strategy would likely
increase identiﬁcation of appropriate candidates for
advanced therapy, we cannot determine the potential impact
of such clinical routines in terms of the extent of increase in
referrals or (potentially unnecessary) testing. But it does not
seem unreasonable that 41% of patients (i.e., with 1 risk
factor) age 80 years, with NYHA functional class III to IV
and EF <40%, get the opportunity for at least a 1-time
expert assessment at an advanced HF center.
Study limitations. The 5 risk factors were chosen based
on their universal availability and their known independent
prognostic power, but were not prospectively validated as
the best predictors in our population. However, our aim
was not to validate predictors with optimal resolution but
to provide simple, universally available, and memorable
criteria that can help generalist clinicians identify patients
for referral. Furthermore, the unselective nature, large
number of patients, and large number of variables for
multivariable analyses lend reliability and generalizability to
the ﬁndings.Conclusions
Among unselected patients with NYHA functional class
III to IV HF and EF <40%, the death of patients up to age
80 years is primarily death related to HF and/or its
comorbidities and may therefore be served by advanced HF
therapy. The presence of 1 or more universally available risk
factors conferred a 1-year survival of 79% or worse. We
propose that the presence of 1 or more risk factors should be
a trigger for generalists to refer to an advanced HF center for
optimization and potentially evaluation for HTx, LVAD,
palliative care, or other potential interventions.Acknowledgments
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